KKR & Co. agreed to acquire Integer Holdings for $5.89 billion in August, making the medical device manufacturer the largest private equity transaction of a month that otherwise saw global dealmaking contract sharply. Healthcare accounted for the majority of capital deployment in August PE activity, with Integer representing nearly half of the month's disclosed deal value in the sector. The transaction closes in Q4 2025, subject to regulatory clearance and Integer shareholder approval.

Global private equity dealmaking fell 37% month-over-month in August, with total disclosed volume landing near $22 billion across all sectors. Healthcare absorbed $11.8 billion of that figure, driven almost entirely by the Integer acquisition and two smaller cardiovascular platform consolidations in Europe. Outside healthcare, only technology and industrials exceeded $2 billion in aggregate deal value. The August decline follows a June and July that posted combined quarterly volume above $140 billion, suggesting seasonal compression rather than structural retreat. KKR's willingness to deploy nearly $6 billion into a single asset during a shallow month signals conviction in healthcare's insulation from rate volatility.

Integer manufactures components for cardiac rhythm management, neuromodulation, and vascular access devices—categories with durable reimbursement profiles and limited exposure to elective procedure cycles. The company reported $1.51 billion in trailing revenue and operating margins near 18%, with 68% of sales derived from implantable cardiac devices. KKR's healthcare platform already includes Envision Healthcare and a portfolio of specialty pharma and med-tech assets totaling more than $40 billion in enterprise value. The Integer acquisition consolidates KKR's position as the largest private capital holder in the cardiac rhythm supply chain, with upstream exposure to Boston Scientific, Medtronic, and Abbott Laboratories. That footprint creates pricing leverage in a sector where device manufacturers are already negotiating tighter margins with hospital procurement groups.

The timing matters because healthcare dealmaking activity diverged from broader PE trends in Q3. While technology and consumer PE exits fell 52% year-over-year, healthcare exits rose 19%, with median hold periods compressing from 6.4 years to 5.1 years. That acceleration suggests sponsors are finding liquidity in healthcare secondaries and strategics at valuations that justify early monetization. KKR's entry into Integer at a 14.2x trailing EBITDA multiple—above the 12.1x sector median—indicates expectation of multiple expansion through operational improvement rather than market recovery. The firm has historically exited med-tech assets at 16x to 18x multiples after hold periods of 4 to 5 years, implying a base case return threshold north of 20% IRR.

Allocators should watch for two follow-on developments. First, whether KKR initiates a carve-out or tuck-in strategy within Integer's neuromodulation division, which represents 22% of revenue but operates at lower margins than cardiac. Precedent suggests KKR will divest or spin that unit within 18 months to concentrate capital on the cardiac platform. Second, whether competing sponsors—specifically Apollo and TPG—respond with counter-bids in adjacent med-tech categories. Apollo has been circling Teleflex's vascular access business since June, and a successful Integer close would validate higher entry multiples across the component supply chain. Regulatory filings for both transactions are expected by mid-October.

Healthcare PE dry powder sits at $187 billion globally, the highest level since 2021, and allocators have been waiting for deployment signals that justify continued commitments to the strategy. Integer provides that signal. The deal is large enough to move sector benchmarks, but narrow enough in its clinical focus to avoid antitrust delay. KKR closes this without syndication risk.